期刊文献+

细胞色素P450酶基因多态性对风湿病药物治疗影响的研究进展

原文传递
导出
摘要 个体化用药目前在医学领域日益受到重视,在风湿病的药物治疗领域更是如此。风湿病药物往往不良反应较多而且严重,其疗效和不良反应存在较大的个体差异。以更科学合理用药为目的的药物遗传学研究目前正在世界范围内迅速发展,已有研究表明,药物存在个体差异主要是因为个体遗传因素不同,特别是涉及药物在体内代谢、转运及排泄过程的酶的基因多态性存在不同。细胞色素P450(cytochrome P450,CYP)酶是多数风湿病药物的主要代谢酶之一,对药物的代谢动力学具有重要影响。本文主要就其基因多态性对风湿病药物治疗影响的研究进展作一综述。
出处 《中华风湿病学杂志》 CAS CSCD 2007年第5期310-312,共3页 Chinese Journal of Rheumatology
基金 深圳市卫生局科技项目专项经费资助(200646) 深圳市医学重点学科建设资助项目(2005C10)
  • 相关文献

参考文献15

  • 1Asanuma Y, Xie HG, Stein CM. Pharmacogenetics and rheumatology: molecular mechanisms contributing to variability in drug response. Arthritis Rheum, 2005, 52: 1349-1359.
  • 2Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenae in vivo and in vitro. Eur J Clin Pharmacol, 2001, 57: 729-735.
  • 3Shimamoto J, Ieiri I, Urae A, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9^*3 allele. Eur J Clin Pharmacol, 2000, 56: 65-68.
  • 4Kirchheiner J, Meineke I, Freytag G, et al. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther, 2002, 72: 62-75.
  • 5Kirchheiner J, Stormer E, Meisel C, et al. Influence of CYP2C9 genetic, polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics, 2003, 13: 473-480.
  • 6Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther, 2004, 75: 204-212.
  • 7Visser LE, van Schaik RH, van Vliet M. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther, 2005, 77: 479-485.
  • 8Sevilla MC, Ortega L, Agundez JA, et al. Leflunomide-induced acute hepatitis. Dig Liver Dis, 2004, 36: 82-84.
  • 9Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum, 2004, 50: 2202-2210.
  • 10Furuta T, Shirai N, Sugimoto M, et al. lnfluence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet, 2005, 20: 153-167.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部